News

When Jill Blackburn’s daughter, Sierra, was diagnosed with pediatric multiple sclerosis (MS) at the age of 15, Blackburn had trouble finding sufficient support and resources. She eventually joined a relevant Facebook group, which she evolved into a nonprofit organization, the Pediatric Multiple Sclerosis Alliance. She now serves as…

People with multiple sclerosis (MS) are more than twice as likely to experience headaches, including migraines, than their healthy counterparts, a study from Greece found. Headaches were also longer and more intense for MS patients, and more likely to lead to the use of acute medication. “These findings suggest that headaches…

The U.S. Food and Drug Administration (FDA) has given Tr1x the green light to launch a first-in-human clinical trial of TRX319, a cell therapy candidate designed to restore immune balance in people with progressive forms of multiple sclerosis (MS). With FDA clearance now granted for its investigational new…

The U.S. Food and Drug Administration (FDA) granted fast track designation to EG110A, EG 427‘s DNA-based therapy to treat neurogenic detrusor overactivity (NDO) — a bladder disorder that can arise from spinal cord injury or neurodegenerative conditions such as multiple sclerosis (MS). The FDA gives fast track status to experimental…

Going through menopause with multiple sclerosis (MS) can be challenging, as the changes that come with this stage of life may interact or occur in tandem with existing MS symptoms. A team of researchers recently studied how menopause affects women living with MS, with their findings presented…

Seizures in people with multiple sclerosis (MS) may be driven by changes in levels of certain brain signaling molecules, implying that targeting these molecules may be a viable strategy to treat MS-related seizures, according to new research done in a mouse model. “If the same transporters and receptors are…

Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation CAR T-cell therapy for multiple sclerosis (MS) and certain blood cancers. The funds come from the Advanced Research Projects Agency for Health’s (ARPA-H) EMBODY program, which aims to support the…

Researchers have identified two experimental medications that may promote myelin repair in people with multiple sclerosis (MS). The two compounds have shown promise in cell and animal models, and preclinical work is ongoing to bring them into clinical testing. The compounds were identified by academic researchers, but the program…

A new grant from the Valhalla Foundation will help Octave Bioscience advance the development of a biomarker blood test for detecting disease progression in people with multiple sclerosis (MS). The company is developing its MS Disease Progression test, or MSDP, to objectively measure MS progression based on…

Quantum Biopharma says it is closer to initiating a Phase 2 clinical trial — one involving people living with multiple sclerosis (MS) — to test its experimental therapy Lucid-MS after receiving the final reports from two toxicology studies requested by the U.S Food and Drug Administration (FDA). The…

Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and other diseases. The deal with orelabrutinib’s developer, Innocare Pharma, includes rights to two other investigational therapies. Zenas will pay Innocare up to $100 million in cash and up to…

Roxy Murray was living up to being known as “The Multiple Sclerosis Fashionista” when she attended the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Barcelona, Spain, on a warm September afternoon. Murray, who has multiple sclerosis (MS) and lives in London, applies her…

Disability progression does not seem to worsen in women with multiple sclerosis (MS) after they undergo menopause, according to the largest study of its kind. Instead, other factors such as older age at MS onset, longer disease duration, and worse initial disability scores were associated with an increased risk…

The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple Sclerosis Society (NMSS) played a central role in many of the advances highlighted there. Nearly 10,000 people attended the 41st Congress of the European Committee for Treatment and Research in Multiple…

Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of multiple sclerosis (MS), with no new safety concerns reported. That’s according to new long-term data from the…

Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs of active inflammation in the brain, a group with limited treatment options. That’s according to new data…

Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in people with primary progressive multiple sclerosis (PPMS). That’s according to top-line data from the Phase 3b GAVOTTE…

Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according to new Phase 4 trial data. The results come from the CLARIFY-MS (NCT03369665) and MAGNIFY-MS (NCT03364036)…

Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with Gilenya (fingolimod), now the only MS therapy approved for pediatric patients in the U.S. That’s according to…

Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years of treatment, while continuing to show a favorable safety profile. That’s according to new data from an…

Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated with increased disease activity in people with clinically isolated syndrome (CIS), which is the first presentation of multiple sclerosis (MS), a study has found. The analysis used a…

Treatment with equecabtagene autoleucel, known for short as eque-cel — Iaso Biotherapeutics‘ CAR T-cell therapy candidate for people with progressive forms of multiple sclerosis (MS) — was well tolerated and led to an easing of disability for five patients taking part in a Phase 1 clinical trial. The…

Combining the diabetes medication metformin and the antihistamine clemastine significantly increased myelin repair in people with relapsing-remitting multiple sclerosis (RRMS), according to results from a Phase 2 clinical trial. However, the effects were small, and participants showed no improvements in disability or visual function after six months of treatment.

Increasing blood vitamin D levels with high-dose supplementation can significantly reduce the risk of new disease activity in people with clinically isolated syndrome (CIS), or those who experienced a first episode of symptoms suggestive of multiple sclerosis (MS). That’s according to new data from the D-Lay-MS…

Aerobic exercise may help promote myelin repair in some parts of the brain in people with multiple sclerosis (MS), according to a small study. Though the study included a small number of participants and followed them for a short period of time, the findings suggest that “supporting metabolic health…

Some older people with multiple sclerosis (MS), namely those older than 60, may be able to safely discontinue disease-modifying therapies (DMTs) as long as they continue to be regularly monitored for new disease activity, a new study suggests. The findings showed that people older than 50 generally experience an…

A stem cell transplant may offer better long-term results for people with aggressive multiple sclerosis (MS) compared with standard high-efficacy drug treatment, according to new evidence presented at a major European conference this week. Specifically, researchers found that an autologous hematopoietic stem cell transplant (aHSCT) was superior to…

People with multiple sclerosis (MS) seem to experience significant changes in cognition more than a year before significant physical decline is evident, a study found. While measures of processing speed, verbal memory, and visual memory worsened after about 2.7 years, significant changes in walking function and dexterity were only…

Following the MIND diet, a program that focuses on brain health, may help reduce disability, ease fatigue, and improve quality of life for people with multiple sclerosis (MS), according to an analysis of data from a U.K. database. The diet, which combines aspects of the Mediterranean and the Dietary…

The new revisions to the McDonald criteria for multiple sclerosis (MS) —  a set of guidelines long used to diagnose the neurodegenerative condition — have increased the proportion of people who can be diagnosed with MS and also allow for earlier diagnoses. That’s according to a new analysis…